A clinical study has shown that coexpression of both HER2 and EpCAM at high levels correlates with poor prognosis in breast cancer patients [39], suggesting that a drug targeting both these moieties would be highly beneficial to these high-risk patients. The gene discussed is EPCAM; the disease is breast cancer.